ZLÍNSKÁ, Vladimíra, Vaclav MATOUSEK, Lukáš TRANTÍREK and Riccardo RIGO. Fluorine Labeling as a Versatile Tool for Probing Nucleic Acid Folding and Interactions by NMR Spectroscopy. ALDRICHIMICA ACTA. UNITED STATES: ALDRICH CHEMICAL CO INC, 2022, vol. 55, No 2, p. 45-52. ISSN 0002-5100.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Fluorine Labeling as a Versatile Tool for Probing Nucleic Acid Folding and Interactions by NMR Spectroscopy
Authors ZLÍNSKÁ, Vladimíra (203 Czech Republic, belonging to the institution), Vaclav MATOUSEK, Lukáš TRANTÍREK (203 Czech Republic, belonging to the institution) and Riccardo RIGO (380 Italy, belonging to the institution).
Edition ALDRICHIMICA ACTA, UNITED STATES, ALDRICH CHEMICAL CO INC, 2022, 0002-5100.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10401 Organic chemistry
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.600
RIV identification code RIV/00216224:14740/22:00128812
Organization unit Central European Institute of Technology
UT WoS 000923599400003
Keywords in English F-19 NMR spectroscopy; F-19 probes; DNA; RNA; F-19-labeling approaches; nucleic acid folding; nucleic acid/small molecule interactions; nucleic acid/protein interactions; in vitro; in vivo
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 8/3/2023 09:36.
Abstract
This mini-review provides an overview of approaches to F-19-labeling of nucleic acids. A special attention is paid to applications of F-19-labeled nucleic acids to resolve their polymorphism and characterize their folding and interactions with ligands and proteins in vitro and in living cells by using NMR spectroscopy.
Links
EF20_079/0017045, research and development projectName: MSCAfellow4@MUNI
NV19-08-00450, research and development projectName: Atomárně rozlišená NMR spektroskopie in vivo jako nástroj pro biologické testování terapeuticky významných cílů v genomové ne-kanonické DNA a jejich interakcí s léčivy ve fenotypově diverzifikovaných nádorových buňkách.
Investor: Ministry of Health of the CR
PrintDisplayed: 29/7/2024 02:35